Strategic Advocates LLC Has $215,000 Holdings in DaVita Inc. (NYSE:DVA)

Strategic Advocates LLC trimmed its position in shares of DaVita Inc. (NYSE:DVA) by 27.3% in the 4th quarter, Holdings Channel reports. The institutional investor owned 1,437 shares of the company’s stock after selling 539 shares during the period. Strategic Advocates LLC’s holdings in DaVita were worth $215,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Transcendent Capital Group LLC acquired a new stake in DaVita in the third quarter valued at approximately $25,000. Blue Trust Inc. lifted its stake in shares of DaVita by 56.4% in the 3rd quarter. Blue Trust Inc. now owns 330 shares of the company’s stock valued at $54,000 after purchasing an additional 119 shares during the last quarter. Quarry LP acquired a new position in DaVita during the third quarter worth $60,000. Versant Capital Management Inc raised its holdings in DaVita by 58.7% during the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock valued at $68,000 after buying an additional 169 shares in the last quarter. Finally, ORG Wealth Partners LLC acquired a new stake in shares of DaVita in the third quarter worth about $97,000. Institutional investors own 90.12% of the company’s stock.

DaVita Stock Performance

DVA opened at $176.62 on Friday. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78. The stock’s 50 day moving average price is $159.50 and its two-hundred day moving average price is $154.77. The firm has a market capitalization of $14.48 billion, a P/E ratio of 19.05, a price-to-earnings-growth ratio of 0.85 and a beta of 0.92. DaVita Inc. has a 12-month low of $107.74 and a 12-month high of $178.75.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. During the same period last year, the firm posted $2.85 EPS. The company’s revenue was up 4.6% compared to the same quarter last year. On average, equities analysts forecast that DaVita Inc. will post 9.71 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Barclays raised their price objective on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Truist Financial boosted their price objective on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company. According to MarketBeat, DaVita presently has a consensus rating of “Hold” and a consensus target price of $161.80.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.